longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Pfizer

PFE

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 36.23, above the reasonable range, cheaper than 14.71% of the time in the past 3 years, and the industry ranks 48/257, the industry Median -1.31.

36.23xP/E
$27.55Stock price
$0.76Earnings per share
36.23xP/E
Stock price$27.55Earnings per share$0.76

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
17.65x
Typical range
12.96x–34.93x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
JNJUSJohnson & Johnson
30.61x18.50%$643.92B
PFEUSPfizer
36.23x16.59%$157.03B
AMRXUSAmneal Pharmaceuticals
33.79x122.71%$5.32B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.